EN / 中文
您的位置： 首页 > 2023年3月 第38卷 第3期 > 文字全文
2023年7月 第38卷 第7期11
目录

重视对髓鞘少突胶质细胞糖蛋白抗体阳性视神经炎的再认识

Pay attention to the re-understanding of myelin oligodendrocyte glycoprotein antibody-positive optic neuritis

来源期刊： 眼科学报 | 2023年3月 第38卷 第3期： 175-180 发布时间：2023-03-01 收稿时间：2023/3/24 16:56:54 阅读量：6623
作者：
宋宏鲁,
魏世辉,
关键词：
髓鞘少突胶质细胞糖蛋白抗体视神经炎临床特征治疗进展
myelin oligodendrocyte glycoprotein antibody optic neuritis clinical characteristics treatment advancement
DOI：
10.12419/j.issn.1000-4432.2023.03.01
视神经炎(optic neuritis,ON)是指视神经的炎性脱髓鞘病变，是引起中青年人视力下降的主要原因。近年来，髓鞘少突胶质细胞糖蛋白抗体阳性视神经炎(myelin oligodendrocyte glycoprotein antibody-positive ON,MOG-ON)成为神经眼科领域的研究热点，国内外报道不断增加。2021年3月，中华医学会眼科学分会神经眼科学组制定了《中国脱髓鞘性视神经炎诊断和治疗循证指南(2021年)》，将MOG-ON作为新的视神经炎亚型纳入脱髓鞘性视神经炎的诊疗体系，给广大眼科医生提供了新的参考依据。因此，临床医生需要充分认识MOG抗体相关疾病和MOG-ON的临床特征和治疗进展，努力提高其诊断和治疗水平，使此类患者能够得到更多的获益，造福于更多的视神经疾病患者。
Optic neuritis(ON)is an inflammatory demyelinating disease of the optic nerve, which is the main cause of vision loss in young and middle-aged people. In recent years, myelin oligodendrocyte glycoprotein antibody-positive ON(MOG-ON)has become a research hotspot in the field of neuro-ophthalmology, and reports at home and abroad are increasing.In March 2021, the Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association formulated the Evidence-Based Guidelines for the Diagnosis and Treatment of Demyelinating Optic Neuritis in China(2021) , and included MOG-ON as a new optic neuritis subtype in the diagnosis and treatment system of myelinating optic neuritis providing a new reference for the majority of ophthalmologists. Therefore, clinicians need to fully understand the clinical features and treatment progress of MOG antibody-related diseases and MOG-ON, and strive to improve the level of diagnosis and treatment, so that such patients can get more benefits and benefit more patients with optic nerve diseases.
    视神经炎(optic neuritis,ON)是指视神经的炎性脱髓鞘病变，可导致急性或亚急性视力下降，是引起中青年人视功能损害的主要原因。水通道蛋白4(aquaporin 4,AQP4)抗体和髓鞘少突胶质细胞糖蛋白(myel in oligodendrocyte glycoprotein,MOG)抗体成为ON诊断必不可少的生物标志物，改变了眼科医生对于典型性ON的理解和认识[1]。近几年，MOG抗体阳性视神经炎(MOG antibody-positive ON,MOG-ON)成为神经眼科领域的研究热点，国内外报道不断增加[2-5]。2021年3月，中华医学会眼科学分会神经眼科学组制定了《中国脱髓鞘性视神经炎诊断和治疗循证指南(2021年)》[6]，将MOG-ON作为新的ON亚型纳入脱髓鞘性视神经炎的诊疗体系，给广大眼科医生提供了新的参考依据。因此，临床医生需要充分认识MOG-ON的临床特征，努力提高对该病的诊断和治疗水平，使患者能够得到更多的获益，造福于更多的视神经疾病患者。

1 MOG抗体与MOG抗体相关疾病

    MOG抗原是一种1型跨膜蛋白，表达于少突胶质细胞的细胞膜上，属于免疫球蛋白超家族[7]。虽然，MOG仅占中枢神经系统(central nervous system,CNS)髓鞘蛋白成分的0.05%，但又是CNS髓鞘成分中抗原性最强的蛋白[8]。21世纪初，MOG抗体曾被误认为是多发性硬化(multiple sclerosis,MS)的特异性生物标志物[9]，早期MOG抗体的检测方法是酶联免疫吸附实验(enzyme linked immunosorbent assay,ELISA)法，随着检测技术的发展出现了灵敏度和特异度更高的基于细胞的检测(cell-based assays,CBA)法[10]。ELISA法能识别的线性表位的MOG抗体不具有致病性，而CBA法能识别构象表位的MOG抗体具有致病性，通过CBA法检测MOG抗体证实了MS患者的MOG抗体阳性率极低，由此确定MOG抗体阳性与MS发生无直接的关系。
    目前，主流观点认为MOG抗体是MOG抗体相关疾病(MOG antibody-associated disease,MOGAD)主要的生物标志物，MOGAD是一种不同于MS和视神经脊髓炎谱系疾病(neuromyelitis optica spectrum disorder,NMOSD)的独立的疾病谱[11-12]。2015年，国际NMOSD诊断标准是在MOGAD被确认为一个独立疾病实体之前制定的，约21%~42%的AQP4抗体阴性NMOSD患者的MOG 抗体呈阳性[13-14]。MOGAD的临床表型比NMOSD更加广泛，仅有约1/3的MOGAD患者符合AQP4抗体阴性的NMOSD诊断标准[15-16]。AQP4抗体和MOG抗体同时阳性NMOSD病例极为罕见，表明了NMOSD和MOGAD并非由共同的病理生物学机制介导[17]。另外，MOGAD病理标本显示的脱髓鞘病灶不伴有星形胶质细胞变性，这与NMOSD并不相同[18]。MOGAD病灶可广泛累及CNS，临床表现多样化，包括ON、横贯性脊髓炎、急性播散性脑脊髓炎(acute disseminated encephalomyelitis, AEDM)和脑干脑炎等[15, 19]，可为单一症状或者以上症状的多种组合。

2 MOG-ON临床特征

    ON是MOGAD最常见的临床分型，ADEM在儿童患者中更常见。MOG-ON患者男女比例相当，临床表现多种多样，主要特征包括视盘水肿多见、容易双眼发病和复发率较高[2-3]。MOG-ON更常见于儿童患者[4-5]，与中青年患者相比，儿童患者具有不同的临床特征，具有更好的视力恢复、更低的年复发率和更多的颅内段视神经受累[20]。MOG-ON和AQP4-ON急性期引起的视力下降通常都很严重，但MOG-ON患者的视力恢复结局明显优于AQP4-ON患者[2, 21]；仅有6%~10%MOG-ON患者的最终视力低于0.1，而AQP4-ON患者的最终视力低于0.1的比例通常超过1/3[2, 21-22]。笔者团队的一项最新研究结果显示：首次发病时有73.2%MOG-ON患者伴视盘水肿(AQP4-ON占比为38.2%)，45.0%MOG-ON患者首次发病即表现为双眼同时受累或短期内双眼先后受累(AQP4-ON占比为12.6%)；随访结束时MOG-ON患者出现严重视力下降(BCVA≤0.1)比例(15/254；5.9%)明显低于AQP4-ON(236/550；42.9%)和双抗体阴性ON组(68/218；31.2%)[5]。
    部分MOG-ON患者对于糖皮质激素(激素)治疗反应敏感，但又存在着明显的激素依赖性，表现为激素减量或者停用后容易复发，这一特征符合慢性复发性炎性视神经病变(chronic relapsing inflammatory optic neuropathy,CRION)诊断标准[23-24]，而AQP4-ON患者很少出现这类情况[25]。MOG抗体阳性可以表现为短暂性或者一过性，约63%MOG-ON患者的抗体水平在发病14个月后降至检测线以下[26]，而AQP4抗体一旦阳性，通常会持续多年。MOG抗体持续阳性的患者更易复发，并且MOG抗体滴度的降低与疾病的单时相病程有关[27]。使用免疫抑制剂治疗期间，血清MOG抗体滴度可以降低或者转阴[28]。MOG抗体可以在其他CNS炎症性疾病中检测到，例如与抗N-甲基-D-天冬氨酸受体(anti-N-methyl-D-aspartate receptor,NMDAR)抗体共存[29]。
    不同亚型ON的眼眶MRI检查表现存在差异性。在MOG-ON患者中，视神经增强信号可以发生在视神经周围，甚至延续到眶内组织，这在其他亚型的ON中很少见到[2, 30-31]。AQP4-ON常有长节段的视神经受累，其中视交叉和视束受累相对常见[31]。近期一项研究表明MOG-ON患者视交叉受累的比例高达16%，在这些患者中约54%存在长节段广泛的视神经增强信号[32]。由于MRI视神经受累特点不同，可以为不同亚型ON诊断及鉴别提供线索，建议对所有非典型ON患者进行眼眶MRI检查[6]。

3 MOG-ON治疗进展

    目前，MOG-ON治疗研究数据有限，治疗推荐多来自一些小样本、回顾性研究，缺乏统一治疗方案，参考和借鉴专家共识和相关疾病的治疗指南具有重要意义[6, 11-33]。MOG-ON的治疗通常分为两个阶段：急性期治疗和缓解期治疗。急性期治疗的目的是最大限度地挽救视功能，防止或减少对CNS的进一步损害；维持期治疗主要目的是为了减少疾病的复发，降低失明和致残的严重程度。
    大剂量甲泼尼龙冲击治疗(intravenous methyl-prednisolone,IVMP)是MOG-ON患者急性期的一线治疗。最近的一项回顾性研究表明，早期IVMP治疗可以改善MOG-ON患者的视力预后[34]。对于部分IVMP治疗不敏感的患者，可使用血浆置换(plasma
exchange,PE)治疗。国外研究表明，对于IVMP治疗无效的MOGAD患者经PE治疗后的预后有改善[28]。笔者研究表明，PE治疗可以有效改善ON患者的视力[35]。因此，当伴有严重视力下降的MOG-ON患者经IVMP治疗效果欠佳时，PE是一种可行的治疗选择。对于IVMP治疗无反应或反应差，或病情逐渐恶化的MOGAD患者，静脉注射免疫球蛋白(intravenous immunoglobulin,IVIG)治疗有助于快速控制症状并减少复发[36]。日本学者进行的一项多中心、前瞻性、双盲、随机对照试验表明，IVIG可作为IVMP治疗不敏感ON急性期患者安全有效的治疗选择[37]。
    MOG-ON患者的维持期治疗的最佳方案还不确定，期待着国内外同行开展更多的“头对头”(直接比较研究)的临床试验，筛选更优的治疗方案。多项研究表明，MOG-ON加用经典的免疫抑制治疗，包括小剂量激素、硫唑嘌呤、吗替麦考酚酯(mycophenolate mofetil,MMF)、利妥昔单抗(rituximab,RTX)和定期IVIG，可以降低疾病复发的频率，但不能完全预防复发[38-43]。一项来自13个国家29个中心的回顾性研究发现，RTX降低了MOGAD的复发率，尽管B淋巴细胞显著减少(血液中CD19+B淋巴细胞比例<1%)，但仍有不少患者继续复发[44]。笔者研究发现，MMF和RTX均能降低MOG-ON患者的疾病活动程度，RTX表现出比MMF更好的耐受性；因为不加用免疫抑制治疗的MOG-ON患者中仅有不到一半会复发[45]，因此，首次发病后暂时不推荐免疫抑制剂治疗仍然是一个不错的选择。据报道，托珠单抗有助于稳定复发性MOG-ON患者的病情[46-47]，还需要开展更多的高质量临床研究来验证。最后还需要指出，传统的MS疾病修饰治疗对MOG-ON患者无效，甚至可能使患者的病情加重或恶化[40-41]。

4 展望

    AQP4抗体和MOG抗体的发现加深了眼科医生对ON的认识，两种特异性抗体的检测有助于不同亚型ON患者的诊断、治疗和随访。推荐非典型ON患者进行AQP4抗体和MOG抗体筛查。针对NMOSD发病机制中的关键环节的新型的免疫靶向药物研发，比如选择性补体C5抑制剂、IL-6受体抑制剂、B淋巴细胞消耗剂，这些药物的上市已成为治疗AQP4-ON的里程碑事件。新型免疫靶向药物的成功上市为我们深入研究MOGAD发病机制提振了信心，坚信在不久的将来就会出现针对MOG-ON发病机制中的特异性靶向药物；此外，干细胞治疗、抗VEGF治疗、基因治疗可能会是潜在有效的措施，有待于更加深入的基础和临床研究；同时呼吁国内从事神经眼科的医生齐心协力、通力合作，积极开展和参与国际和国内的多中心视神经疾病的临床研究项目，尽快搭建和完善我国的神经眼科疾病数据库平台，积累更多的国人自己的循证医学证据，更好地服务于MOG-ON患者。

开放获取声明

本文适用于知识共享许可协议 (Creative Commons)，允许第三方用户按照署名(BY)-非商业性使用(NC)-禁止演绎(ND)(CCBY-NC-ND)的方式共享，即允许第三方对本刊发表的文章进行复制、发行、展览、表演、放映、广播或通过信息网络向公众传播，但在这些过程中必须保留作者署名、仅限于非商业性目的、不得进行演绎创作。详情请访问：https://creativecommons.org/licenses/by-nc-nd/4.0/。
1、Beck R, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis[ J]. The Optic Neuritis Study Group. N Engl J Med, 1992, 326(9): 581-588.Beck R, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis[ J]. The Optic Neuritis Study Group. N Engl J Med, 1992, 326(9): 581-588.
2、Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome[ J]. Am J Ophthalmol, 2018, 195: 8-15.Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome[ J]. Am J Ophthalmol, 2018, 195: 8-15.
3、Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin[ J]. J Neuroinflammation, 2016, 13(1): 279.Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin[ J]. J Neuroinflammation, 2016, 13(1): 279.
4、Song H, Zhou H, Yang M, et al. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China[ J]. Br J Ophthalmol, 2019, 103(6): 831-836.Song H, Zhou H, Yang M, et al. Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China[ J]. Br J Ophthalmol, 2019, 103(6): 831-836.
5、Yang M, Wu Y, Song H, et al. Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies[ J]. Am J Ophthalmol, 2022, 239: 11-25.Yang M, Wu Y, Song H, et al. Vision prognosis and associated factors of optic neuritis in dependence of glial autoimmune antibodies[ J]. Am J Ophthalmol, 2022, 239: 11-25.
6、中华医学会眼科学分会神经眼科学组, 兰州大学循证医学中 心/世界卫生组织指南实施与知识转化合作中心. 中国脱髓鞘 性视神经炎诊断和治疗循证指南(2021年)[ J]. 中华眼科杂志, 2021, 57(3): 171-186.
Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Evidence-based Medicine Center of Lanzhou University/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation. Evidence-based guidelines for diagnosis and treatment of demyelinating optic neuritis in China(2021)[ J] Chinese Journal of Ophthalmology, 2021, 57(3): 171-186.中华医学会眼科学分会神经眼科学组, 兰州大学循证医学中 心/世界卫生组织指南实施与知识转化合作中心. 中国脱髓鞘 性视神经炎诊断和治疗循证指南(2021年)[ J]. 中华眼科杂志, 2021, 57(3): 171-186.
Neuro-ophthalmology Group of Ophthalmology Branch of Chinese Medical Association, Evidence-based Medicine Center of Lanzhou University/World Health Organization Collaborating Centre for Guideline Implementation and Knowledge Translation. Evidence-based guidelines for diagnosis and treatment of demyelinating optic neuritis in China(2021)[ J] Chinese Journal of Ophthalmology, 2021, 57(3): 171-186.
7、Breithaupt C, Schubart A, Zander H, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein[ J]. Proc Natl Acad Sci U S A, 2003, 100(16): 9446-9451.Breithaupt C, Schubart A, Zander H, et al. Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein[ J]. Proc Natl Acad Sci U S A, 2003, 100(16): 9446-9451.
8、Shao H, Huang Z, Sun SL, et al. Myelin/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL/6 mouse[ J]. Invest Ophthalmol Vis Sci, 2004, 45(11): 4060-4065.Shao H, Huang Z, Sun SL, et al. Myelin/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL/6 mouse[ J]. Invest Ophthalmol Vis Sci, 2004, 45(11): 4060-4065.
9、Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event[ J]. N Engl J Med, 2003, 349(2): 139-145.Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event[ J]. N Engl J Med, 2003, 349(2): 139-145.
10、Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination[ J]. Autoimmun Rev, 2016, 15(4): 307-324.Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination[ J]. Autoimmun Rev, 2016, 15(4): 307-324.
11、中国免疫学会神经免疫分会. 抗髓鞘少突胶质细胞糖蛋白免疫 球蛋白G抗体相关疾病诊断和治疗中国专家共识[ J]. 中国神经 免疫学和神经病学杂志, 2020, 27(2): 86-95.
Neuroimmune Branch of the Chinese Immunological Society. Chinese expert consensus on diagnosis and treatment of diseases related to anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibody[ J] Chinese Journal of Neuroimmunology and Neurology, 2020, 27(2): 86-95.中国免疫学会神经免疫分会. 抗髓鞘少突胶质细胞糖蛋白免疫 球蛋白G抗体相关疾病诊断和治疗中国专家共识[ J]. 中国神经 免疫学和神经病学杂志, 2020, 27(2): 86-95.
Neuroimmune Branch of the Chinese Immunological Society. Chinese expert consensus on diagnosis and treatment of diseases related to anti-myelin oligodendrocyte glycoprotein immunoglobulin G antibody[ J] Chinese Journal of Neuroimmunology and Neurology, 2020, 27(2): 86-95.
12、中国免疫学会神经免疫分会. 中国视神经脊髓炎谱系疾病诊 断与治疗指南(2021版)[ J]. 中国神经免疫学和神经病学杂志, 2021, 28(6): 423-436.
Neuroimmune Branch of Chinese Immunolog ical Soc iet y. Chinese Guidelines for the Diagnosis and Treatment of Optic Neuromyelitis Pedigree Diseases(2021 Edition)[ J]. Chinese Journal of Neuroimmunology and Neurology, 2021, 28(6): 423-436.中国免疫学会神经免疫分会. 中国视神经脊髓炎谱系疾病诊 断与治疗指南(2021版)[ J]. 中国神经免疫学和神经病学杂志, 2021, 28(6): 423-436.
Neuroimmune Branch of Chinese Immunolog ical Soc iet y. Chinese Guidelines for the Diagnosis and Treatment of Optic Neuromyelitis Pedigree Diseases(2021 Edition)[ J]. Chinese Journal of Neuroimmunology and Neurology, 2021, 28(6): 423-436.
13、Hamid SHM, Whiam D, Mutch K, et al. What proportion of AQP4- IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol, 2017, 264(10): 2088- 2094.Hamid SHM, Whiam D, Mutch K, et al. What proportion of AQP4- IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. J Neurol, 2017, 264(10): 2088- 2094.
14、Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders[ J]. Neurology, 2014, 82(6): 474-481.Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders[ J]. Neurology, 2014, 82(6): 474-481.
15、Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study[ J]. Brain, 2017, 140(12): 3128-3138.Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study[ J]. Brain, 2017, 140(12): 3128-3138.
16、Jarius S, Kleiter I, Ruprecht K , et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement-frequency, presentation and outcome[ J]. J Neuroinflammation, 2016, 13(1): 281.Jarius S, Kleiter I, Ruprecht K , et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement-frequency, presentation and outcome[ J]. J Neuroinflammation, 2016, 13(1): 281.
17、Kunchok A, Chen JJ, McKeon A, et al. Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients[ J]. JAMA Neurol, 2020, 77(2): 257-259.Kunchok A, Chen JJ, McKeon A, et al. Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients[ J]. JAMA Neurol, 2020, 77(2): 257-259.
18、H?ftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendroc y te glycoprotein autoantibody[ J]. Acta Neuropathol, 2020, 139(5): 875-892.H?ftberger R, Guo Y, Flanagan EP, et al. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendroc y te glycoprotein autoantibody[ J]. Acta Neuropathol, 2020, 139(5): 875-892.
19、Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosi s and anti body testing[ J]. J Neuroinflammation, 2018, 15(1): 134.Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosi s and anti body testing[ J]. J Neuroinflammation, 2018, 15(1): 134.
20、Song H, Zhou H, Yang M, et al. Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China[ J]. J Neurol Sci, 2019, 400: 83-89.Song H, Zhou H, Yang M, et al. Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: a cohort study in China[ J]. J Neurol Sci, 2019, 400: 83-89.
21、Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis[ J]. Ophthalmology, 2018, 125(10): 1628- 1637.Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis[ J]. Ophthalmology, 2018, 125(10): 1628- 1637.
22、Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis[ J]. J Neurol Sci, 2010, 298(1/2): 158-162.Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis[ J]. J Neurol Sci, 2010, 298(1/2): 158-162.
23、Liu H, Zhou H, Wang J, et al. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy[ J]. Br J Ophthalmol, 2019, 103(10): 1423-1428.Liu H, Zhou H, Wang J, et al. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy[ J]. Br J Ophthalmol, 2019, 103(10): 1423-1428.
24、Lee HJ, Kim B, Waters P, et al. Chronic relapsing inammatory optic neuropathy(CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies[ J]. J Neuroinflammation, 2018, 15(1): 302.Lee HJ, Kim B, Waters P, et al. Chronic relapsing inammatory optic neuropathy(CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies[ J]. J Neuroinflammation, 2018, 15(1): 302.
25、Liu H, Zhou H, Wang J, et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis[ J]. J Neurol Sci, 2019, 396: 225-231.Liu H, Zhou H, Wang J, et al. The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis[ J]. J Neurol Sci, 2019, 396: 225-231.
26、Pr?bstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis[ J]. Neurology, 2011, 77(6): 580-588.Pr?bstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis[ J]. Neurology, 2011, 77(6): 580-588.
27、López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders[ J]. JAMA Neurol, 2018, 75(11): 1355-1363López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders[ J]. JAMA Neurol, 2018, 75(11): 1355-1363
28、Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome[ J]. J Neuroinflammation, 2016, 13(1): 280.Jarius S, Ruprecht K, Kleiter I, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome[ J]. J Neuroinflammation, 2016, 13(1): 280.
29、Du L, Wang H, Zhou H, et al. Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: a retrospective observational study[ J]. Medicine(Baltimore), 2020, 99(31): e21238.Du L, Wang H, Zhou H, et al. Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: a retrospective observational study[ J]. Medicine(Baltimore), 2020, 99(31): e21238.
30、Akaishi T, Sato DK, Nakashima I, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study[ J]. J Neurol Neurosurg Psychiatry, 2016, 87(4): 446-448.Akaishi T, Sato DK, Nakashima I, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study[ J]. J Neurol Neurosurg Psychiatry, 2016, 87(4): 446-448.
31、Dutra BG, José da Rocha A, Nunes RH, et al. Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis-erratum[ J]. Radiographics, 2018, 38(2): 662.Dutra BG, José da Rocha A, Nunes RH, et al. Neuromyelitis optica spectrum disorders: spectrum of MR imaging findings and their differential diagnosis-erratum[ J]. Radiographics, 2018, 38(2): 662.
32、Tajrouz D, Padungkiatsagul T, Beres S, et al. Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder[ J]. Mult Scler, 2022, 28(1): 149-153.Tajrouz D, Padungkiatsagul T, Beres S, et al. Optic chiasm involvement in AQP-4 antibody-positive NMO and MOG antibody-associated disorder[ J]. Mult Scler, 2022, 28(1): 149-153.
33、中国免疫学会神经免疫分会, 中华医学会神经病学分会神经免 疫学组. 多发性硬化诊断和治疗中国专家共识(2018版)[ J]. 中 国神经免疫学和神经病学杂志, 2018, 25(6): 387-394.
Neuroimmunology Branch of Chinese Immunological Society, Neuroimmunology Group of Neurology Branch of Chinese Medical Association. Chinese expert consensus on diagnosis and treatment of multiple sclerosis(2018)[ J] Chinese Journal of Neuroimmunology and Neurology, 2018, 25(6): 387-394.中国免疫学会神经免疫分会, 中华医学会神经病学分会神经免 疫学组. 多发性硬化诊断和治疗中国专家共识(2018版)[ J]. 中 国神经免疫学和神经病学杂志, 2018, 25(6): 387-394.
Neuroimmunology Branch of Chinese Immunological Society, Neuroimmunology Group of Neurology Branch of Chinese Medical Association. Chinese expert consensus on diagnosis and treatment of multiple sclerosis(2018)[ J] Chinese Journal of Neuroimmunology and Neurology, 2018, 25(6): 387-394.
34、Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?[ J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6(4): e572.Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?[ J]. Neurol Neuroimmunol Neuroinflamm, 2019, 6(4): e572.
35、Tan S, Ng TK, Xu Q, et al. Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study[ J]. Ther Adv Neurol Disord, 2020, 13:1756286420947977Tan S, Ng TK, Xu Q, et al. Vision improvement in severe acute isolated optic neuritis after plasma exchange treatment in Chinese population: a prospective case series study[ J]. Ther Adv Neurol Disord, 2020, 13:1756286420947977
36、Bruijstens AL, Breu M, Wendel EM, et al. E.U. paediatric MOG consortium consensus: part 4-Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders[ J]. Eur J Paediatr Neurol, 2020, 29: 32-40.Bruijstens AL, Breu M, Wendel EM, et al. E.U. paediatric MOG consortium consensus: part 4-Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders[ J]. Eur J Paediatr Neurol, 2020, 29: 32-40.
37、Mimura O, Ishikawa H, Kezuka T, et al. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study[ J]. Jpn J Ophthalmol, 2021, 65(1): 122-132.Mimura O, Ishikawa H, Kezuka T, et al. Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study[ J]. Jpn J Ophthalmol, 2021, 65(1): 122-132.
38、Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study[ J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(3): e705.Li S, Ren H, Xu Y, et al. Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: a prospective study[ J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(3): e705.
39、Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease[ J]. J Neuroinammation, 2019, 16(1): 134.Cobo-Calvo A, Sepúlveda M, Rollot F, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease[ J]. J Neuroinammation, 2019, 16(1): 134.
40、Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease[ J]. JAMA Neurol, 2018, 75(4): 478-487.Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease[ J]. JAMA Neurol, 2018, 75(4): 478-487.
41、Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder[ J]. Neurology, 2020, 95(2): e111-e120.Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder[ J]. Neurology, 2020, 95(2): e111-e120.
42、Nepal G, Kharel S, Coghlan MA, et al. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G(MOG-IgG)-associated disorders(MOGAD): a systematic review and meta-analysis[ J]. J Neuroimmunol, 2022, 364: 577812.Nepal G, Kharel S, Coghlan MA, et al. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G(MOG-IgG)-associated disorders(MOGAD): a systematic review and meta-analysis[ J]. J Neuroimmunol, 2022, 364: 577812.
43、Thakolwiboon S, Zhao-Fleming H, Karukote A, et al. Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder[ J]. Mult Scler Relat Disord, 2021, 56: 103310.Thakolwiboon S, Zhao-Fleming H, Karukote A, et al. Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder[ J]. Mult Scler Relat Disord, 2021, 56: 103310.
44、Whittam DH, Cobo-Calvo A, Lopez-Chiriboga A S, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients[ J]. Mult Scler Relat Disord, 2020, 44: 102251.Whittam DH, Cobo-Calvo A, Lopez-Chiriboga A S, et al. Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients[ J]. Mult Scler Relat Disord, 2020, 44: 102251.
45、Xie L , Zhou H , Song H , et al . Comparative analysis of immunosuppressive therapies for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a cohort study[ J]. Br J Ophthalmol, 2022, 106(11): 1587-1595.Xie L , Zhou H , Song H , et al . Comparative analysis of immunosuppressive therapies for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a cohort study[ J]. Br J Ophthalmol, 2022, 106(11): 1587-1595.
46、Hayward-Koennecke H, Reindl M, Martin R , et al. Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis[ J]. Neurology, 2019, 92(16): 765-767.Hayward-Koennecke H, Reindl M, Martin R , et al. Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis[ J]. Neurology, 2019, 92(16): 765-767.
47、Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders[ J]. Neurol Neuroimmunol Neuroinamm, 2022, 9(1): e1100.Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders[ J]. Neurol Neuroimmunol Neuroinamm, 2022, 9(1): e1100.
1、国家重点研发计划项目(2018YFE0113900)；国家自然科学基金面上项目(81870662)。
This work was supported by the National Key Research and Development Program (2018YFE0113900)；National Natural Science Foundation of China (81870662).()
上一篇
下一篇
作者登录
作者注册
审稿登录
编辑登录
其他期刊

  • 眼科学报

    主管：中华人民共和国教育部
    主办：中山大学
    承办：中山大学中山眼科中心
    主编：林浩添
    主管：中华人民共和国教育部
    主办：中山大学
    浏览

  • Eye Science

    主管：中华人民共和国教育部
    主办：中山大学
    承办：中山大学中山眼科中心
    主编：林浩添
    主管：中华人民共和国教育部
    主办：中山大学
    浏览
最新资讯

基于深度学习和智能手机的眼病预防与远程诊疗

英文标题dmeo

发布于: 2022-12-01

一亿年进化出的晶状体有多重要？

英文标题dmeo

发布于: 2022-12-01

《眼科学报》由季刊变更为月刊

英文标题dmeo

发布于: 2022-12-01
推荐阅读
出版者信息
中山眼科


中山大学
目录
中山大学医学期刊联盟
关注微信公众号
首页   | 关于我们  | 联系我们 2022 眼科学报 版权所有
关注微信公众号
粤ICP备11021180